# AEGON (AGN.AS) - Investment Thesis

**Date**: 2026-01-31
**Analyst**: Claude (Fundamental Analyst)
**Recommendation**: **CONDITIONAL BUY** (see caveats)
**Price at analysis**: EUR 6.58
**Fair Value Range**: EUR 8.40 - 9.00
**Margin of Safety**: 22-27%

---

## 1. Executive Summary

Aegon is a 180-year-old Dutch insurance/financial services company undergoing a strategic transformation into a US-focused life insurance and retirement group. Trading at 7.4x forward earnings, 1.1x book, and yielding 5.8%, Aegon offers value characteristics. The company generates EUR 1.2B in operating capital annually, has a strong solvency ratio (188%), and is returning significant capital via dividends (+5%/yr growth) and buybacks (EUR 400M in 2026).

**The key catalyst and risk is the same event**: relocation of HQ to the US and rebranding as Transamerica Inc. (target: Jan 2028). This is a transformational move that simplifies structure but introduces execution risk and a EUR 350M one-time cost.

---

## 2. Business Overview

| Metric | Value |
|--------|-------|
| Market Cap | EUR 10.0B |
| Sector | Insurance - Diversified |
| Employees | 15,500 |
| HQ | The Hague, Netherlands (relocating to US) |
| Key Brands | Transamerica, World Financial Group (WFG) |
| Solvency II Ratio | 188% (Dec 2024) |

### Geographic Mix (~70% US)
- **Americas (Transamerica)**: ~70% of operations. Life insurance, annuities, retirement plans, mutual funds. Distributes via WFG and institutional channels.
- **United Kingdom**: Workplace pensions, asset management. GBP 2.1B net deposits H1 2025. **Under strategic review** (potential divestment).
- **International**: Brazil, China, Spain/Portugal. Growth markets.
- **Netherlands**: Sold to ASR Nederland in 2022. Aegon retains 29.99% stake in ASR.

### Revenue/Earnings Trajectory
- Revenue volatile (insurance accounting effects): ~EUR 19.5B (2024)
- Operating result H1 2025: EUR 845M (+19% YoY)
- OCG 2024: EUR 1.2B (met guidance). 2025 target: EUR 1.2B (on track after 9M).
- Net income: EUR 688M (2024), EUR 606M (H1 2025 alone)

---

## 3. Moat Assessment: **NARROW**

| Factor | Assessment |
|--------|------------|
| Switching costs | **Moderate**. Life insurance/pension contracts are sticky. Retirement plans have high inertia. |
| Scale | **Moderate**. Large US footprint in retirement ($275B AuA target by 2027). Not top-3 but significant. |
| Distribution | **Moderate-Strong**. WFG network is a proprietary distribution advantage, growing 13% in new life sales. |
| Brand | **Weak in US** (Transamerica less known than MetLife/Prudential). **Moderate in Europe**. |
| Regulatory moat | **Moderate**. Insurance is heavily regulated, creating barriers to entry. |
| Cost advantage | **None evident**. |

**Moat verdict: NARROW**. Switching costs in life/pensions + WFG distribution network + regulatory barriers provide a narrow but real moat. Not wide because Aegon lacks pricing power or dominant market share in any segment.

---

## 4. Valuation

### Method 1: Book Value Based
- GAAP book value/share: EUR 5.85
- Valuation equity/share (IFRS operating): EUR 8.91
- Current P/B: 1.12x
- Justified P/B (ROE 15%, COE 10%, g 3%): 1.71x
- **Fair value**: EUR 8.91 - 10.03

### Method 2: Earnings/OCG Based
- Forward EPS: EUR 0.89 | OCG/share: EUR 0.80
- At 10x forward P/E: EUR 8.90
- At 9% OCG yield: EUR 8.87
- **Fair value**: EUR 8.87 - 8.93

### Method 3: Dividend Discount Model
- Dividend 2025E: EUR 0.40 | Growth: 5%/yr | Discount: 10%
- **Fair value**: EUR 8.40

### Synthesis

| Method | Fair Value | MoS vs EUR 6.58 |
|--------|-----------|-----------------|
| Justified P/B | EUR 10.03 | 34% |
| 1.0x Valuation Equity | EUR 8.91 | 26% |
| 10x Forward P/E | EUR 8.90 | 26% |
| 9% OCG Yield | EUR 8.87 | 26% |
| DDM | EUR 8.40 | 22% |
| **Average** | **EUR 9.02** | **27%** |
| **Conservative** | **EUR 8.40** | **22%** |

**Central fair value: EUR 8.90 | Conservative: EUR 8.40**

---

## 5. Risk Assessment

| # | Risk | Probability | Impact | P x I | Mitigation |
|---|------|------------|--------|-------|------------|
| 1 | **US HQ relocation execution risk** - EUR 350M cost, regulatory/tax complexity, 2-3 year process | Medium (40%) | High | **HIGH** | Management experienced; dual listing maintained |
| 2 | **US mortality/longevity adverse trends** - Already impacted assumptions in 2025 | Medium (50%) | Medium | **MEDIUM-HIGH** | SGUL reinsurance (80% addressed); assumption updates taken |
| 3 | **UK strategic review uncertainty** - Divestment could be at unfavorable price | Medium (35%) | Medium | **MEDIUM** | UK is ~15% of ops; workplace business performing well |
| 4 | **Interest rate sensitivity** - Lower rates compress investment income | Medium (30%) | Medium | **MEDIUM** | Diversified investment portfolio; hedging programs |
| 5 | **Regulatory/political risk** - US insurance regulation changes, Dutch withholding tax on relocation | Low-Med (25%) | High | **MEDIUM** | Relocation addresses regulatory simplification |
| 6 | **Correlation with existing portfolio (ALL)** - Both insurance, though different geographies/lines | Low | Low | **LOW** | Correlation only 0.31 (weekly, 2y). AGN is life/retirement vs ALL is P&C. Low overlap. |

---

## 6. Margin of Safety Analysis

| Scenario | Fair Value | MoS |
|----------|-----------|-----|
| Bull (12x P/E, execution success) | EUR 10.70 | 38% |
| Base (10x P/E) | EUR 8.90 | 26% |
| Bear (8x P/E, relocation issues) | EUR 7.12 | 8% |
| Conservative (DDM) | EUR 8.40 | 22% |

**The base case MoS of 26-27% barely meets our 25% threshold. The conservative DDM-based MoS of 22% falls short.**

---

## 7. Investment Decision: **CONDITIONAL BUY**

### Why BUY (arguments for):
1. Trading at 7.4x forward earnings and 5.8% yield with >5% dividend growth commitment
2. OCG of EUR 1.2B/yr is well-covered and stable
3. Massive capital return: EUR 400M buyback (2026) + growing dividend = ~10% total yield
4. Solvency ratio 188% provides substantial buffer
5. US retirement market is secular growth (aging demographics, pension reform)
6. Low correlation (0.31) with existing ALL position
7. 15 analysts covering a EUR 10B mid-cap = moderate coverage, some inefficiency potential

### Why CAUTION:
1. **MoS is borderline** (26-27% base, 22% conservative). Does not provide comfortable buffer.
2. **Relocation is transformational** - EUR 350M cost, 2-3 year execution, shareholder vote needed Q4 2026
3. **UK strategic review** adds uncertainty
4. **FCF from yfinance is inconsistent** with company-reported OCG (yfinance shows EUR 696M vs company EUR 1.2B OCG). Insurance accounting is complex.
5. **Reduced disclosure** - stopping quarterly trading updates in 2026-2027

### Recommendation:
**CONDITIONAL BUY at EUR 5.90-6.10** (would provide 30-34% MoS to base case). At current EUR 6.58, the margin is thin. I recommend:

1. **Add to watchlist** with target entry at EUR 5.90-6.10
2. **Monitor**: Q4 2025 results (Feb 2026), shareholder vote on relocation (Q4 2026)
3. If price drops 10% to ~EUR 5.90 on any volatility, execute buy at 2-3% position size

### Position Sizing (if bought):
- Initial: 2.5% (below 7% max)
- Sector: Insurance would be ALL (3.5%) + AGN (2.5%) = 6% (below 25% sector limit)
- Geography: Mainly US exposure (~70%), consistent with diversification goals

---

## 8. Autocritica

**Assumptions made**:
- ROE sustains ~15% (could be lower if mortality trends worsen)
- OCG of EUR 1.2B is maintainable (company has delivered 2 years running)
- Dividend growth of 5% is sustainable (payout ratio ~45% leaves room)
- Relocation proceeds without major regulatory obstacles

**Biases checked**:
- Not recommending just because it screens cheap - identified real risks
- Compared vs alternatives (NN Group, LGEN.L) rather than analyzing in isolation
- Used 5 independent valuation methods to triangulate

**What I cannot verify**:
- Quality of US insurance reserves (opaque by nature)
- True economic value of SGUL book after reinsurance
- Impact of relocation on tax rate and capital efficiency

---

## Sources
- [Aegon H2 2024 Results](https://www.globenewswire.com/news-release/2025/02/20/3029279/0/en/Aegon-reports-second-half-year-2024-results.html)
- [Aegon H1 2025 Results](https://www.globenewswire.com/news-release/2025/08/21/3136822/0/en/Aegon-reports-first-half-year-2025-results.html)
- [Aegon CMD Dec 2025](https://www.globenewswire.com/news-release/2025/12/10/3202903/0/en/Aegon-Capital-Markets-Day-2025-The-Next-Frontier.html)
- [Aegon Q3 2025 Trading Update](https://www.globenewswire.com/news-release/2025/11/13/3186994/0/en/Aegon-trading-update-for-third-quarter-2025.html)
- yfinance data (AGN.AS) as of 2026-01-31
